3550 related articles for article (PubMed ID: 19302902)
1. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
2. Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii.
Deal EN; Micek ST; Ritchie DJ; Reichley RM; Dunne WM; Kollef MH
Pharmacotherapy; 2007 Feb; 27(2):191-9. PubMed ID: 17253909
[TBL] [Abstract][Full Text] [Related]
3. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.
Goethaert K; Van Looveren M; Lammens C; Jansens H; Baraniak A; Gniadkowski M; Van Herck K; Jorens PG; Demey HE; Ieven M; Bossaert L; Goossens H
Clin Microbiol Infect; 2006 Jan; 12(1):56-62. PubMed ID: 16460547
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
[TBL] [Abstract][Full Text] [Related]
5. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
6. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
7. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.
Lodise TP; Patel N; Kwa A; Graves J; Furuno JP; Graffunder E; Lomaestro B; McGregor JC
Antimicrob Agents Chemother; 2007 Oct; 51(10):3510-5. PubMed ID: 17646415
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and predictors of mortality in patients with Enterobacter aerogenes bacteremia.
Chang EP; Chiang DH; Lin ML; Chen TL; Wang FD; Liu CY
J Microbiol Immunol Infect; 2009 Aug; 42(4):329-35. PubMed ID: 19949757
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
[TBL] [Abstract][Full Text] [Related]
10. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
[TBL] [Abstract][Full Text] [Related]
11. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
[TBL] [Abstract][Full Text] [Related]
12. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome.
Nseir S; Di Pompeo C; Cavestri B; Jozefowicz E; Nyunga M; Soubrier S; Roussel-Delvallez M; Saulnier F; Mathieu D; Durocher A
Crit Care Med; 2006 Dec; 34(12):2959-66. PubMed ID: 17012911
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
[TBL] [Abstract][Full Text] [Related]
14. Resistance patterns among selective Gram-negative bacilli from an intensive care unit in Trinidad, West Indies.
Orrett FA
Saudi Med J; 2004 Apr; 25(4):478-83. PubMed ID: 15083220
[TBL] [Abstract][Full Text] [Related]
15. Enterobacter bacteremia: Clinical features, risk factors for multiresistance and mortality in a Chinese University Hospital.
Ye Y; Li JB; Ye DQ; Jiang ZJ
Infection; 2006 Oct; 34(5):252-7. PubMed ID: 17033748
[TBL] [Abstract][Full Text] [Related]
16. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected?
Schechner V; Nobre V; Kaye KS; Leshno M; Giladi M; Rohner P; Harbarth S; Anderson DJ; Karchmer AW; Schwaber MJ; Carmeli Y
Clin Infect Dis; 2009 Mar; 48(5):580-6. PubMed ID: 19191643
[TBL] [Abstract][Full Text] [Related]
17. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
[TBL] [Abstract][Full Text] [Related]
18. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004.
Paul M; Gafter-Gvili A; Leibovici L; Bishara J; Levy I; Yaniv I; Shalit I; Samra Z; Pitlik S; Konigsberger H; Weinberger M
Isr Med Assoc J; 2007 Jun; 9(6):424-9. PubMed ID: 17642387
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
[TBL] [Abstract][Full Text] [Related]
20. Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study.
Alves MD; Ribeiro VB; Tessari JP; Mattiello F; De Bacco G; Luz DI; Vieira FJ; Behle TF; Pasqualotto AC; Zavascki AP
J Antimicrob Chemother; 2014 Jun; 69(6):1681-7. PubMed ID: 24474430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
